Suppr超能文献

人非孕子宫肌层中前列腺素TP受体群体的特征分析。

Characterization of the prostanoid TP receptor population in human nonpregnant myometrium.

作者信息

Senchyna M, Crankshaw D J

机构信息

Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.

出版信息

J Pharmacol Exp Ther. 1996 Oct;279(1):262-70.

PMID:8859002
Abstract

We have used both functional and binding studies to fully characterize the prostanoid TP receptor in the myometrium from nonpregnant human donors. Both U-46,619 and I-BOP produced concentration-dependent contraction of human myometrial strips in vitro (pEC50 = 6.9 +/- 0.6; and 7.8 +/- 0.5, respectively). U-46,619-induced contractions were attenuated by the TP receptor antagonists: ICI 192,605 (pKB = 9.2 +/- 0.3); ICI D1,542 (pKB = 9.1 +/- 0.3); L670,596 (pKB = 8.6 +/- 0.3); GR 32,191 (pKB = 8.6 +/- 0.2); SQ 29,548 (pKB = 8.2 +/- 0.5); ONO 3,708 (pKB = 8.1 +/- 0.3) and BM 13,505 (pKB = 7.4 +/- 0.2). The binding of [125I]-BOP to human myometrial membranes was saturable, selective and displaceable. Equilibrium binding of [125I]-BOP identified one class of sites, Kd = 3.4 nM (pKd = 8.7 +/- 0.4) and a maximum binding of 323.1 +/- 361.5 fmol/mg protein. The addition of the nonhydrolyzable GTP analog GTP gamma S (100 microM) to the assay had no effect on [125I]-BOP binding. The Kd determined kinetically was 4.1 +/- 0.2 nM. TP receptor antagonists competed for [125I]-BOP binding: ICI D1,542 (pIC50 = 8.3 +/- 0.4); L670,596 (pIC50 = 7.9 +/- 0.1); ICI 192,605 (pIC50 = 7.2 +/- 0.1); ONO 3,708 (pIC50 = 7.2 +/- 0.04); SQ 29,548 (pIC50 = 7.2 +/- 0.1); GR 32,191 (pIC50 = 7.0 +/- 0.2); BM 13,505 (pIC50 = 6.8 +/- 0.1). The rank order of potency for the seven TP receptor antagonists in displacing [125I]-BOP from its binding site was correlated (r = 0.75) with the rank order of potency in inhibiting U-46,619-induced contraction of myometrial strips. Ligands selective for other prostanoid receptors were unable to significantly displace [125I]-BOP binding. These results are consistent with the notion that the human myometrial TP receptor is pharmacologically similar to the low affinity TP receptor in human platelets.

摘要

我们通过功能研究和结合研究,对来自非妊娠人类供体子宫肌层中的前列腺素TP受体进行了全面表征。U-46,619和I-BOP均可在体外引起人子宫肌条的浓度依赖性收缩(pEC50分别为6.9±0.6和7.8±0.5)。U-46,619诱导的收缩可被TP受体拮抗剂减弱:ICI 192,605(pKB = 9.2±0.3);ICI D1,542(pKB = 9.1±0.3);L670,596(pKB = 8.6±0.3);GR 32,191(pKB = 8.6±0.2);SQ 29,548(pKB = 8.2±0.5);ONO 3,708(pKB = 8.1±0.3)和BM 13,505(pKB = 7.4±0.2)。[125I]-BOP与人子宫肌层膜的结合具有饱和性、选择性和可置换性。[125I]-BOP的平衡结合鉴定出一类位点,Kd = 3.4 nM(pKd = 8.7±0.4),最大结合量为323.1±361.5 fmol/mg蛋白质。向测定中加入不可水解的GTP类似物GTPγS(100μM)对[125I]-BOP结合无影响。动力学测定的Kd为4.1±0.2 nM。TP受体拮抗剂竞争[125I]-BOP结合:ICI D1,542(pIC50 = 8.3±0.4);L670,596(pIC50 = 7.9±0.1);ICI 192,605(pIC50 = 7.2±0.1);ONO 3,708(pIC50 = 7.2±0.04);SQ 29,548(pIC50 = 7.2±0.1);GR 32,191(pIC50 = 7.0±0.2);BM 13,505(pIC50 = 6.8±0.1)。七种TP受体拮抗剂从其结合位点置换[125I]-BOP的效力顺序与抑制U-46,619诱导的子宫肌条收缩的效力顺序相关(r = 0.75)。对其他前列腺素受体有选择性的配体不能显著置换[125I]-BOP结合。这些结果与人类子宫肌层TP受体在药理学上与人类血小板中的低亲和力TP受体相似的观点一致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验